The goal for this renewal application is to a) elucidate oncogenic Kras (Kras*)-regulated metabolic pathways mediating pancreatic ductal adenocarcinoma (PDAC) tumor maintenance, b) define collateral metabolic dependencies, and c) establish how interventions targeting these processes influence tumor immunity, in order to guide the design of clinical trials with existing drugs and to identify new therapeutic points of attack. Our P01 program comprises 3 highly interdependent and collaborative projects and 4 essential cores with the goals of conquering PDAC through targeting metabolic vulnerabilities in conjunction with immunotherapy. Project 1 has demonstrated that Kras* extinction in PDAC leads to pronounced tumor regression that involves critical functions of Kras* in metabolic reprogramming. We have also identified Kras*-extinction resistant cells (KRCs), which show dramatic adaptive metabolic changes (in OXPHOS and autophagy) allowing survival upon Kras* inactivation. These studies thereby provide benchmarks for successfully targeting Kras* in vivo and predicting resistance mechanisms that may be encountered in the clinic. Thus, the goal of Project 1 is to kill the bulk Kras*-dependent tumor cells through identification of metabolic targets essential for Kras*-mediated PDAC maintenance and to define methods to eliminate KRC through inhibiting autophagy and OXPHOS survival mechanisms. Project 2 has discovered that PDAC is dependent on lysosome-dependent nutrient scavenging pathways for metabolic homeostasis and tumor growth, and has identified a transcriptional program that activates these processes. The goal of Project 2 is to decipher how lysosomal scavenging supports PDAC growth and how cancer cells can escape their dependence on these processes, thereby informing improved therapeutic approaches. Project 2 will identify the metabolic outputs of lysosomal mediated recycling pathways, establish which of these outputs play roles in PDAC growth, and explore metabolic escape pathways in order to identify novel therapeutic combinations synergizing with lysosomal inhibition. Project 3 has defined profound alterations in the tumor microenvironment, including a prominent CD8 T cell infiltration following Kras* extinction in PDAC. Project 3 will define the immune profiles throughout the genesis, regression and recurrence of PDAC and will determine the causal role of CD8 and CD4 cells in PDAC regression, as well as explore new opportunities to test the efficacy of checkpoint blockade therapy and assess the associated adaptive mechanisms underlying immune suppression. Furthermore, Project 3 will determine the direct impact of metabolically targeted therapy on tumor immunity and define effective methods to combine such therapies with immune checkpoint blockade therapy. Highly innovative cores for Pathology, Preclinical Therapeutics, Computation, and an Administrative Core will enable these Projects.
Program Narrative ? (Genetics and Biology of Pancreatic Ductal Adenocarcinoma) Pancreatic cancer will be the second leading cause of cancer death in 15 years and remains incurable. This program project aims to identify therapeutic intervention points through various state-of-the-art technologies and animal modeling. The goal remains to gain sufficient understanding of PDAC genetics and biology to inform the implementation of effective therapeutic combinations.
|Hill, Margaret A; Alexander, William B; Guo, Bing et al. (2018) Kras and Tp53 Mutations Cause Cholangiocyte- and Hepatocyte-Derived Cholangiocarcinoma. Cancer Res 78:4445-4451|
|Mendt, Mayela; Kamerkar, Sushrut; Sugimoto, Hikaru et al. (2018) Generation and testing of clinical-grade exosomes for pancreatic cancer. JCI Insight 3:|
|Patra, Krushna C; Kato, Yasutaka; Mizukami, Yusuke et al. (2018) Mutant GNAS drives pancreatic tumourigenesis by inducing PKA-mediated SIK suppression and reprogramming lipid metabolism. Nat Cell Biol 20:811-822|
|Anglin, Justin; Zavareh, Reza Beheshti; Sander, Philipp N et al. (2018) Discovery and optimization of aspartate aminotransferase 1 inhibitors to target redox balance in pancreatic ductal adenocarcinoma. Bioorg Med Chem Lett 28:2675-2678|
|Yang, Annan; Herter-Sprie, Grit; Zhang, Haikuo et al. (2018) Autophagy Sustains Pancreatic Cancer Growth through Both Cell-Autonomous and Nonautonomous Mechanisms. Cancer Discov 8:276-287|
|Santana-Codina, Naiara; Roeth, Anjali A; Zhang, Yi et al. (2018) Oncogenic KRAS supports pancreatic cancer through regulation of nucleotide synthesis. Nat Commun 9:4945|
|Lundquist, Mark R; Goncalves, Marcus D; Loughran, Ryan M et al. (2018) Phosphatidylinositol-5-Phosphate 4-Kinases Regulate Cellular Lipid Metabolism By Facilitating Autophagy. Mol Cell 70:531-544.e9|
|Hopkins, Benjamin D; Pauli, Chantal; Du, Xing et al. (2018) Suppression of insulin feedback enhances the efficacy of PI3K inhibitors. Nature 560:499-503|
|Biancur, Douglas E; Kimmelman, Alec C (2018) The plasticity of pancreatic cancer metabolism in tumor progression and therapeutic resistance. Biochim Biophys Acta Rev Cancer 1870:67-75|
|Chen, Yang; LeBleu, Valerie S; Carstens, Julienne L et al. (2018) Dual reporter genetic mouse models of pancreatic cancer identify an epithelial-to-mesenchymal transition-independent metastasis program. EMBO Mol Med 10:|
Showing the most recent 10 out of 134 publications